Details
| Stereochemistry | MIXED |
| Molecular Formula | C28H38NO4.Br |
| Molecular Weight | 532.51 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CCCCOC1=CC=C(C[N@+]2(C)[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)[C@H](CO)C4=CC=CC=C4)C=C1
InChI
InChIKey=JABDOYKGZCPHPX-XSCYYCMVSA-M
InChI=1S/C28H38NO4.BrH/c1-3-4-16-32-25-14-10-21(11-15-25)19-29(2)23-12-13-24(29)18-26(17-23)33-28(31)27(20-30)22-8-6-5-7-9-22;/h5-11,14-15,23-24,26-27,30H,3-4,12-13,16-20H2,1-2H3;1H/q+1;/p-1/t23-,24+,26+,27-,29?;/m1./s1
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C28H37NO4 |
| Molecular Weight | 451.5977 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491
Butropium Bromide is an anticholinergic and an antispasmodic. It is a Muscarinic receptor antagonist. The drug is used for remission of spasmodic pain in the following diseases: gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia). It is marketed in Japan under the brand name Coliopan.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?D01491 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Coliopan Approved UseRemission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis
and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date1974 |
|||
| Palliative | Coliopan Approved UseRemission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis
and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date1974 |
|||
| Palliative | Coliopan Approved UseRemission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis
and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia) Launch Date1974 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
|
4 mg 1 times / day single, intravenous Studied dose Dose: 4 mg, 1 times / day Route: intravenous Route: single Dose: 4 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Palpitation, Increased thirst... Other AEs: Palpitation Sources: Increased thirst Urination difficulty (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Increased thirst | 4 mg 1 times / day single, intravenous Studied dose Dose: 4 mg, 1 times / day Route: intravenous Route: single Dose: 4 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
| Palpitation | 4 mg 1 times / day single, intravenous Studied dose Dose: 4 mg, 1 times / day Route: intravenous Route: single Dose: 4 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
| Urination difficulty | 1 pt | 4 mg 1 times / day single, intravenous Studied dose Dose: 4 mg, 1 times / day Route: intravenous Route: single Dose: 4 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Endoscopic manometry of the sphincter of Oddi in dogs. Pharmacological effects of anticholinergic and selective antimuscarinic agents. | 1987-05 |
|
| Sensation of aural fullness and its treatment with an autonomic nerve blocking agent. | 1987 |
|
| Effect of glucagon on gastric motility examined by the acetaminophen absorption method and the endoscopic procedure. | 1985 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Can also be administered intramuscularly http://www.ncbi.nlm.nih.gov/pubmed/7182948
Capsules 5 mg:The usual adult dosage for oral use is 6 capsules (30 mg ofbutropium bromide) daily in three divided doses. Tablets 10 mg:The usual adult dosage for oral use is 3 tablets (30 mg ofbutropium bromide) daily in three divided doses. Granules 2 %:The usual adult dosage for oral use is 1.5 g (30 mg ofbutropium bromide) daily in three divided doses.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:43:27 GMT 2025
by
admin
on
Wed Apr 02 07:43:27 GMT 2025
|
| Record UNII |
R3K4503MV7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000081568
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
SUB06037MIG
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
3498
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110820
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
DTXSID1022716
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
31327
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
R3K4503MV7
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
249-375-4
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
m2806
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
C81548
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
C006846
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY | |||
|
29025-14-7
Created by
admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |